Akram Salam Email & Phone Number

Framingham, Massachusetts, United States

• Used analytical HPLC to detect and quantify nine antibiotics in >10 wound dressing extracts in order to determine release characteristics; contributed to method development for the formulation of said dressings

Framingham, Massachusetts, United States

• Worked with a client's scale-up chemical manufacturing arm to optimize (1) purification of hyaluronic acid (HA) from alligator backstrap extracts, and (2) the formulation of said HA into wound dressings leading to an FDA 510(k) submission; utilized a number of filtration strategies as well as anion-exchange chromatography; assessed and reported on final product purity• Imported and reproducibly employed a number of EPA protocols for the assessment of germicidal efficacy of a set of advanced antimicrobial solutions we developed for a client targeting a number of pathogens including Staphylococcus aureus, Pseudomonas aeruginosa, and Candida auris; assisted in antimicrobial formulation development

Atlanta, Georgia

• Discovered a novel antibiotic candidate, castaneroxy A, by innovative approaches to lab’s existing framework for discovering pharmaceutically active chemicals in plants; IP is protected (US62/812,850)• Mentored three visiting graduate students and three undergraduate students on senior thesis research projects, culminating in all earning highest honors and publications• Coordinated volunteers to process plants for extraction and addition to drug screening library to meet tight deadlines• Co-wrote several grant proposals that led to $1 million in federal funding and multiple collaborations• Acquired scientific knowledge of drug development and technical skills culminating in seven publications• Acquired technical skills: building plant extract library, medium throughput screening, chromatography, nuclear magnetic resonance, mass spectrometry, microbiology, human cell culture, and statistical analysis

• Led a consulting team of four to evaluate Prof. Lily Yang’s nanoparticle-based targeted drug delivery platform for cancer treatment (proprietary technology of Migra Therapeutics)• Determined freedom to operate, optimal tech transfer and clinical trial paths, GMP manufacturing process, requisite pharmacological studies, actionable steps for seeking funding and recruiting a CEO• Pitched the technology to a panel of venture capitalists at a gala ceremony

Acted as Theme Director, created the conference’s concept of “Climate Change: The Global Health Response” in a guidebook distributed to the 179 delegates; trained the 13 co-directors on the execution of the theme, moderated debate

• Collaborated with a team of five on a scientific and business plan for Amgen’s lead drug (AM-0466)• Presented business plan to a panel of industry leaders identifying: target indication and patient population, synthesis, bulk production, PK/PD analysis, drug formulation, clinical trial design, unique value proposition and competitors, costs, marketing strategy, and timelines

Rochester, Ny

• Research Assistant in the laboratory of Dr. Benjamin L. Miller• Developed stopped flow kinetics protocol for assessing binding of drugs to HIV-1 FSS RNA• Synthesized hits from dynamic combinatorial chemistry screen against HIV-1 FSS RNA; assessed binding by isothermal titration calorimetry

Doctor Of Philosophy (Phd), Molecular And Systems Pharmacology, Gpa 3.85

Bachelor Of Science (B.S.), Biochemistry, Gpa 3.61

Education record

Russian language studies